FILE 'REGISTRY' ENTERED AT 12:07:25 ON 24 JUL 2007

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JUL 2007 HIGHEST RN 943188-87-2
DICTIONARY FILE UPDATES: 23 JUL 2007 HIGHEST RN 943188-87-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

L1 STR



VAR G1=O/S/N
REP G2=(0-3) CH2
REP G3=(0-3) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 11
GGCAT IS MCY AT 15
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E5 C E1 N AT 13

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L2 STR



VAR G1=O/S/N
REP G2=(0-3) CH2
REP G3=(2-3) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 11
GGCAT IS MCY AT 18
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E5 C E1 N AT 13

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L3 STR



VAR G1=O/S/N
REP G2=(0-3) CH2
REP G3=(0-3) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1 N AT 13

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L4 STR



VAR G1=O/S/N
REP G2=(0-3) CH2
REP G3=(2-3) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1 N AT 13

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L5 (132)SEA FILE=REGISTRY SSS FUL L3 OR L4
L6 77 SEA FILE=REGISTRY SUB=L5 SSS FUL (L1 OR L2)

100.0% PROCESSED 132 ITERATIONS 77 ANSWERS
SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 12:07:25 ON 24 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 24 Jul 2007 VOL 147 ISS 5
FILE LAST UPDATED: 23 Jul 2007 (20070723/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

L7 5 S L6

E1 THROUGH E72 ASSIGNED

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 27 Sep 2006
ACCESSION NUMBER: 2006:1001119 CAPLUS Full-text
DOCUMENT NUMBER: 146:213
TITLE: Pyridone derivatives as potent, orally bioavailable VLA-4 integrin antagonists
AUTHOR(S): Witherington, Jason; Blaney, Emma L.; Bordas, Vincent; Elliott, Richard L.; Gaiba, Alessandra; Garton, Neil; Green, Philip M.; Naylor, Antoinette; Smith, David G.; Spalding, David J.; Takle, Andrew K.; Ward, Robert W.

CORPORATE SOURCE: Department of DMPK and Medicinal Chemistry, Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research Limited, Essex, CM19 5AW, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(21), 5538-5541
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:213

AB A series of pyridone-N-benzylpropanoic acids have been optimized to afford potent orally bioavailable VLA-4 antagonists.

IT **915157-68-5 915157-69-6 915157-70-9**
915157-71-0 915157-72-1 915157-73-2
915157-74-3 915157-75-4 915157-76-5
RL: PAC (Pharmacological activity); BIOL (Biological study)
(optimization of pyridone-N-benzylpropanoic acids as orally bioavailable VLA-4 integrin antagonists)

IT **660439-96-3**
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); BIOL (Biological study)
(optimization of pyridone-N-benzylpropanoic acids as orally bioavailable VLA-4 integrin antagonists)

IT **660439-93-0P 660440-22-2P 660440-23-3P**
915157-77-6P 915157-78-7P 915157-79-8P
915157-80-1P 915157-81-2P 915157-82-3P
915157-83-4P 915157-84-5P 915157-85-6P
915157-86-7P 915157-87-8P 915157-88-9P
915157-89-0P 915157-90-3P 915157-91-4P
915157-93-6P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(optimization of pyridone-N-benzylpropanoic acids as orally bioavailable VLA-4 integrin antagonists)

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 16 May 2006
ACCESSION NUMBER: 2006:453930 CAPLUS Full-text
DOCUMENT NUMBER: 144:480470
TITLE: Pyridone derivatives as potent and selective VLA-4 integrin antagonists. [Erratum to document cited in CA144:403837]
AUTHOR(S): Witherington, Jason; Bordas, Vincent; Gaiba, Alessandra; Green, Phil M.; Naylor, Antoinette; Parr, Nigel; Smith, David G.; Takle, Andrew K.; Ward, Robert W.
CORPORATE SOURCE: Department of Medicinal Chemistry, Neurology & GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research Limited Harlow, Essex, CM19 5AW, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(12), 3341
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The legends to Figures 1b and 3b are incorrect. In Figure 1b, the legend should read: "GASP molecular overlay of 8 (green) and 5 (yellow)". In Figure 3b, the legend should read: "Molecular overlay of 8 (green) and 10 (yellow)".

IT **660439-93-0P 660439-96-3P 660439-99-6P 660440-62-0P 884347-98-2P 884347-99-3P 884348-00-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyridone derivs. as potent and selective VLA-4 integrin antagonists (Erratum))

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 16 Mar 2006
ACCESSION NUMBER: 2006:232883 CAPLUS Full-text
DOCUMENT NUMBER: 144:403837
TITLE: Pyridone derivatives as potent and selective VLA-4 integrin antagonists
AUTHOR(S): Witherington, Jason; Bordas, Vincent; Gaiba, Alessandra; Green, Phil M.; Naylor, Antoinette; Parr, Nigel; Smith, David G.; Takle, Andrew K.; Ward, Robert W.
CORPORATE SOURCE: Department of Medicinal Chemistry, Neurology & GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research Limited, Essex, CM19 5AW, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(8), 2256-2259
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:403837
GI



I

AB A novel series of pyridone inhibitors has been identified through pharmacophore anal., as potent antagonists of VLA-4. Analog I exhibited excellent inhibitory potency.

IT **660439-93-0P 660439-96-3P 660439-99-6P 660440-62-0P 884347-98-2P 884347-99-3P 884348-00-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(pyridone derivs. as potent and selective VLA-4 integrin antagonists)
REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 23 Sep 2005
ACCESSION NUMBER: 2005:1025806 CAPLUS Full-text
DOCUMENT NUMBER: 143:299147
TITLE: Medicine compositions containing pyridone analogs for inhibiting α4-integrin-mediated cell adhesion
INVENTOR(S): Witherington, Jason; Elliott, Richard Leonard
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 36 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005255675	A	20050922	JP 2005-33237	20050209
PRIORITY APPLN. INFO.:			JP 2004-31901 A	20040209

OTHER SOURCE(S): MARPAT 143:299147
AB Medicine compns. containing pyridone analogs and their pharmacol. acceptable salts are claimed for inhibiting α4-integrin-mediated cell adhesion for treatment of related diseases, including chronic inflammatory diseases, asthma, allergy, inflammatory bowel disease, rheumatoid arthritis, atopic dermatitis, multiple sclerosis, organ transplant rejection, cardiovascular disease, diabetes, tumor, central nervous system diseases, etc.
IT **660439-93-0P 660439-94-1P 660439-95-2P**
660439-96-3P 660439-97-4P 660439-98-5P
660439-99-6P 660440-00-6P 660440-01-7P
660440-02-8P 660440-03-9P 660440-05-1P
660440-07-3P 660440-12-0P 660440-13-1P
660440-14-2P 660440-15-3P 660440-16-4P
660440-17-5P 660440-18-6P 660440-19-7P
660440-20-0P 660440-21-1P 660440-22-2P
660440-23-3P 660440-24-4P 660440-25-5P
660440-26-6P 660440-27-7P 660440-28-8P
660440-29-9P 660440-30-2P 660440-31-3P
660440-32-4P 660440-33-5P 660440-34-6P
660440-35-7P 660440-36-8P 660440-37-9P
660440-38-0P 660440-39-1P 660440-40-4P
660440-41-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(medicine compns. containing pyridone analogs for inhibiting α4-integrin-mediated cell adhesion and treating related diseases)

L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 22 Feb 2004

ACCESSION NUMBER: 2004:143107 CAPLUS Full-text
DOCUMENT NUMBER: 140:199207
TITLE: Preparation of pyridones as inhibitors of α4 integrin-mediated cell adhesion.
INVENTOR(S): Witherington, Jason; Elliott, Richard Leonard
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014859	A2	20040219	WO 2003-JP10119	20030808
WO 2004014859	A3	20040415		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493660	A1	20040219	CA 2003-2493660	20030808
AU 2003256069	A1	20040225	AU 2003-256069	20030808
EP 1539696	A2	20050615	EP 2003-784602	20030808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1688548	A	20051026	CN 2003-823831	20030808
JP 2005535702	T	20051124	JP 2004-527373	20030808
US 2005288337	A1	20051229	US 2005-524028	20050209

PRIORITY APPLN. INFO.: GB 2002-18630 A 20020810
WO 2003-JP10119 W 20030808

OTHER SOURCE(S): MARPAT 140:199207
GI



I

AB Title compds. [I; A, B = aryl, heteroaryl; Q = C, CH; QV, QD = 5-7 membered heterocyclyl; D = H, alkyl; R1-R3 = alkyl, halo, alkoxy, OH, cyano, CF3, NO2, alkylthio, amino, CO2H, alkanoyl, amido, NHCOR9, NHSO2R9; R9 = alkyl, cycloalkyl, (substituted) Ph etc.; R4 = H, alkyl, halo, alkoxy; V = O, S, amino, NNO2, NCN; W, X, Y, Z = C, CH, CH2; dotted line = single or double

bond; L = (CH2)r, (CH2)rrO; r = 0-3; rr = 2, 3; J = CR5:CR6, CHR7CHR8, single bond, CHR6; OCHR10, etc.; R5, R6, R10 = H, alkyl; R7, R8 = H, alkyl, cycloalkyl, aryl, heteroaryl, etc.; m, n, p = 0-3; q = 0-2], were prepared as inhibitors of α4 integrin-mediated cell adhesion (no data). Thus, Et 3-[4-[2-oxo-3-[4-(3-o-tolylureido)phenyl]-2H-pyridin-1- ylmethyl]phenyl]propionate and LiOH were stirred at 60° for 30 min in THF/H2O to give after acidification with HCl 3-[3-[2-oxo-3-[4-(3-o-tolylureido)phenyl]-2H-pyridin-1-ylmethyl]phenyl]propionic acid.

IT **660439-93-0P 660439-94-1P 660439-95-2P**
660439-96-3P 660439-97-4P 660439-98-5P
660439-99-6P 660440-00-6P 660440-01-7P
660440-02-8P 660440-03-9P 660440-05-1P
660440-07-3P 660440-12-0P 660440-13-1P
660440-14-2P 660440-15-3P 660440-16-4P
660440-17-5P 660440-18-6P 660440-19-7P
660440-20-0P 660440-21-1P 660440-22-2P
660440-23-3P 660440-24-4P 660440-25-5P
660440-26-6P 660440-27-7P 660440-28-8P
660440-29-9P 660440-30-2P 660440-31-3P
660440-32-4P 660440-33-5P 660440-34-6P
660440-35-7P 660440-36-8P 660440-37-9P
660440-38-0P 660440-39-1P 660440-40-4P
660440-41-5P 660440-62-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridones as inhibitors of α4 integrin-mediated cell adhesion)

FILE 'REGISTRY' ENTERED AT 12:09:19 ON 24 JUL 2007

L8 72 SEA FILE=REGISTRY ABB=ON PLU=ON (660439-93-0/BI OR 660439-96-3/BI OR 660439-99-6/BI OR 660440-22-2/BI OR 660440-23-3/BI OR 660440-62-0/BI OR 660439-94-1/BI OR 660439-95-2/BI OR 660439-97-4/BI OR 660439-98-5/BI OR 660440-00-6/BI OR 660440-01-7/BI OR 660440-02-8/BI OR 660440-03-9/BI OR 660440-05-1/BI OR 660440-07-3/BI OR 660440-12-0/BI OR 660440-13-1/BI OR 660440-14-2/BI OR 660440-15-3/BI OR 660440-16-4/BI OR 660440-17-5/BI OR 660440-18-6/BI OR 660440-19-7/BI OR 660440-20-0/BI OR 660440-21-1/BI OR 660440-24-4/BI OR 660440-25-5/BI OR 660440-26-6/BI OR 660440-27-7/BI OR 660440-28-8/BI OR 660440-29-9/BI OR 660440-30-2/BI OR 660440-31-3/BI OR 660440-32-4/BI OR 660440-33-5/BI OR 660440-34-6/BI OR 660440-35-7/BI OR 660440-36-8/BI OR 660440-37-9/BI OR 660440-38-0/BI OR 660440-39-1/BI OR 660440-40-4/BI OR 660440-41-5/BI OR 884347-98-2/BI OR 884347-99-3/BI OR 884348-00-9/BI OR 915157-68-5/BI OR 915157-69-6/BI OR 915157-70-9/BI OR 915157-71-0/BI OR 915157-72-1/BI OR 915157-73-2/BI OR 915157-74-3/BI OR 915157-75-4/BI OR 915157-76-5/BI OR 915157-77-6/BI OR 915157-78-7/BI OR 915157-79-8/BI OR 915157-80-1/BI OR 915157-81-2/BI OR 915157-82-3/BI OR 915157-83-4/BI OR 915157-84-5/BI OR 915157-85-6/BI OR 915157-86-7/BI OR 915157-87-8/BI OR 915157-88-9/BI OR 915157-89-0/BI OR 915157-90-3/BI OR 915157-91-4/BI OR 915157-93-6/BI)

=> d 1,5,9,18,26,27,29,35,42,58,66,72 ide can

L8 ANSWER 1 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN
RN **915157-93-6** REGISTRY

ED Entered STN: 11 Dec 2006
CN Benzenepropanoic acid, β-methyl-4-[[3-[2-methyl-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, (βS)- (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H31 N3 O4
SR CA
LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 146:213

L8 ANSWER 5 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN
RN **915157-88-9** REGISTRY
ED Entered STN: 11 Dec 2006
CN Benzenepropanoic acid, 4-[[3-[3-ethoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-β-methyl-, (βS)- (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H33 N3 O5
SR CA
LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 146:213

L8 ANSWER 9 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN
RN **915157-84-5** REGISTRY
ED Entered STN: 11 Dec 2006
CN Benzenepropanoic acid, 4-[[3-[2-chloro-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-β-methyl-, (βR)- (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H28 Cl N3 O4
SR CA
LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 146:213

L8 ANSWER 18 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN
RN **915157-75-4** REGISTRY
ED Entered STN: 11 Dec 2006
CN Benzenepropanoic acid, 4-[[3-[4-[[[(2,5-dimethylphenyl)amino]carbonyl]amino]-3-methoxyphenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)
MF C31 H31 N3 O5
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 146:213

L8 ANSWER 26 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN
RN **884348-00-9** REGISTRY
ED Entered STN: 15 May 2006
CN Benzeneacetic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (9CI) (CA INDEX NAME)
MF C28 H25 N3 O4
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 144:480470

REFERENCE 2: 144:403837

L8 ANSWER 27 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN
RN **884347-99-3** REGISTRY
ED Entered STN: 15 May 2006
CN Benzenepropanoic acid, 2-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (9CI) (CA INDEX NAME)
MF C29 H27 N3 O4
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 144:480470

REFERENCE 2: 144:403837

L8 ANSWER 29 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN
RN **660440-62-0** REGISTRY
ED Entered STN: 09 Mar 2004
CN Benzenepropanoic acid, 3-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (9CI) (CA INDEX NAME)
MF C29 H27 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 144:480470

REFERENCE 2: 144:403837

REFERENCE 3: 140:199207

L8 ANSWER 35 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN
RN **660440-36-8** REGISTRY
ED Entered STN: 09 Mar 2004
CN Benzenepropanoic acid, 3-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)
MF C29 H31 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 143:299147

REFERENCE 2: 140:199207

L8 ANSWER 42 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN
RN **660440-29-9** REGISTRY
ED Entered STN: 09 Mar 2004
CN Benzenepropanoic acid, 4-[[3-[4-[[(2,3-dihydro-1H-indol-1-yl)carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (9CI) (CA INDEX NAME)
MF C30 H27 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 143:299147

REFERENCE 2: 140:199207

L8 ANSWER 58 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN
RN **660440-13-1** REGISTRY
ED Entered STN: 09 Mar 2004
CN Benzeneacetic acid, 4-[2-[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)
MF C29 H27 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 143:299147

REFERENCE 2: 140:199207

L8 ANSWER 66 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN
RN **660439-99-6** REGISTRY

ED Entered STN: 09 Mar 2004
CN Benzoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (9CI) (CA INDEX NAME)
MF C27 H23 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 144:480470

REFERENCE 2: 144:403837

REFERENCE 3: 143:299147

REFERENCE 4: 140:199207

L8 ANSWER 72 OF 72 REGISTRY COPYRIGHT 2007 ACS on STN
RN **660439-93-0** REGISTRY
ED Entered STN: 09 Mar 2004
CN Benzenepropanoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)
MF C29 H27 N3 O4
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 146:213

REFERENCE 2: 144:480470

REFERENCE 3: 144:403837

REFERENCE 4: 143:299147

REFERENCE 5: 140:199207

FILE 'CAOLD' ENTERED AT 12:11:20 ON 24 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGlstRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L9 0 L6

FILE 'MEDLINE' ENTERED AT 12:11:29 ON 24 JUL 2007

FILE 'BIOSIS' ENTERED AT 12:11:29 ON 24 JUL 2007

FILE 'EMBASE' ENTERED AT 12:11:29 ON 24 JUL 2007

L10 0 L6

=> fil hom
FILE 'HOME' ENTERED AT 12:11:39 ON 24 JUL 2007

FILE 'CAPLUS' ENTERED AT 15:13:07 ON 20 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 15:13:07 ON 20 JUL 2007

FILE 'BIOSIS' ENTERED AT 15:13:07 ON 20 JUL 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 15:13:07 ON 20 JUL 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'WPIX' ENTERED AT 15:13:07 ON 20 JUL 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'JAPIO' ENTERED AT 15:13:07 ON 20 JUL 2007
COPYRIGHT (C) 2007 Japanese Patent Office (JPO)- JAPIO

FILE 'PASCAL' ENTERED AT 15:13:07 ON 20 JUL 2007
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2007 INIST-CNRS. All rights reserved.

FILE 'DISSABS' ENTERED AT 15:13:07 ON 20 JUL 2007
COPYRIGHT (C) 2007 ProQuest Information and Learning Company; All Rights Res
erved.

```
L15          205 SEA ABB=ON  PLU=ON  "WITHERINGTON J"?/AU
L16         6337 SEA ABB=ON  PLU=ON  "ELLIOTT R"?/AU
L17           12 SEA ABB=ON  PLU=ON  L15 AND L16
L18           24 SEA ABB=ON  PLU=ON  (L15 OR L16) AND ((ALPHA4 OR A4 OR (A
                 OR ALPHA)(W) 4)(3A) INTEGRIN OR (CD49? OR CD 49)(5A)
                 ANTIGEN OR (CELL OR CELLULAR)(3A) ADHESION)
L19           30 SEA ABB=ON  PLU=ON  L17 OR L18
L20           16 DUP REM L19 (14 DUPLICATES REMOVED)
```

L20 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2007:33257 CAPLUS Full-text
DOCUMENT NUMBER: 146:142654
TITLE: Preparation of imidazopyridines as acid pump antagonists
INVENTOR(S): Bamford, Mark James; **Elliott, Richard Leonard**; Giblin, Gerard Martin Paul; Naylor, Antoinette; Panchal, Terence Aaron; Takle, Andrew Kenneth; **Witherington, Jason**
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 40pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007003386	A1	20070111	WO 2006-EP6410	20060628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,				

GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2005-13423 A 20050630

OTHER SOURCE(S): MARPAT 146:142654

GI



I

AB Title compds. [I; X = NH, NR7, O; R1 = H, alkyl, CH2CN, CH2NH2, cycloalkyl, alkenyl, alkynyl, fluoroalkyl, alkylsulfonylalkyl, amino, etc.; R2 = alkyl, amino, cycloalkyl, cycloalkylalkyl, alkoxy, alkenyl, hydroxyalkyl, cyanoalkyl, haloalkyl, etc.; R3 = H, alkyl; R4, R5 = H, alkyl, OH, halo, amino, alkoxy; R3R4 = atoms to form (substituted) 5-6 membered heterocyclic ring; R6 = H, alkyl, halo, OH, amino, alkoxycarbonylamino; R7 = alkyl; R4R7 = atoms to form (substituted) 5-7 membered heterocyclyl; Y = (substituted) 4-7 membered nonarom. heterocyclyl], were prepared Thus, 6-bromo-N-[(2,6-dimethylphenyl)methyl]-2,3-dimethylimidazo[1,2-a]pyridin-8-amine, 2-pyrrolidinone, tris(dibenzylidineacetone)dipalladium, 4,5-bis(diphenylphosphino)-9,9-dimethylxanthine, and Cs2CO3 were refluxed together in dioxane to give 1-[8-[[(2,6- dimethylphenyl)methyl]amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl]-2- pyrrolidinone hydrochloride. I inhibited H+/K+ ATPase at <5 μM.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2007:281174 CAPLUS Full-text
DOCUMENT NUMBER: 146:330828
TITLE: Pharmaceutical compositions containing . **alpha.-4 integrin** mediated **cell adhesion** inhibitors
INVENTOR(S): Ward, Robert William; **Witherington, Jason**
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 38pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007063268	A	20070315	JP 2006-212923	20060804
PRIORITY APPLN. INFO.:			JP 2005-227980 A	20050805

OTHER SOURCE(S): MARPAT 146:330828
GI



AB The invention relates to a pharmaceutical composition characterized by containing a compound I [A, B, D = aryl, heteroaryl; R1, R2, R3 = C1-6 alkyl, halogen, C1-6 alkoxy, hydroxy, cyano, CF3, OCF3, nitro, C1-6 alkylthio, amino, mono-(di-)-C1-6 alkylamino, carboxy, C1-6 alkanoyl, amido, mono-(di-)-C1-6 alkylamido, etc; R4, R4' = H, C1-6 alkyl, halogen, C1-6 alkoxy; V = O, S, NH, N-C1-6 alkyl, NNO2, NCN; W, X, Y, Z = C, CH, N, wherein at least on of X, Y, and Z is N; L = -(CH2)q-, -(CH2)q'O-, wherein q = 0=3, q' = 2, 3; J = -CR5:CR6-, wherein R5, R6 = H, C1-6 alkyl, single bond, etc.; m, n, p = 0-3; t = 0-2], or its pharmaceutically acceptable derivative as an active component. The compound has an inhibitory effect against **α-4 integrin** mediated **cell adhesion**, and is suitable for use for treatment of **α-4 integrin** mediated **cell adhesion**-related disease, e.g. asthma, enteritis, rheumatic arthritis, and multiple sclerosis, etc. For example, a compound (R,S)-3-[4-[5-[3-ethoxy-4-(3-o- tolylureido)phenyl]-6-oxo-6H-pyrimidin-1-ylmethyl]phenyl]butyric acid was prepared, and examined for its interaction with integrin VLA-4 in vitro.

L20 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2007:613414 CAPLUS Full-text
TITLE: Therapeutic approaches towards the treatment of gastrointestinal disorders
AUTHOR(S): Collingwood, Steve; **Witherington, Jason**
CORPORATE SOURCE: UK
SOURCE: Drug News & Perspectives (2007), 20(2), 139-144
CODEN: DNPEED; ISSN: 0214-0934
PUBLISHER: Prous Science
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. The Society for Medicines Research gathered an international panel of speakers and about 60 delegates for their symposium Sept. 21, 2006, on

Therapeutic Approaches Towards the Treatment of Gastrointestinal Disorders, at the National Heart and Lung Institute, in London, U.K. The focus of the conference was to discuss therapeutic strategies taken towards the treatment of inflammatory bowel disease, acid-related disorders and irritable bowel syndrome. Key note lectures addressed the development of tegaserod, a 5-HT4 receptor agonist, for the treatment of constipation dominant irritable bowel syndrome (cIBS), the use of tumor necrosis factor α (TNFα) inhibitors in the treatment of chronic inflammatory diseases, including Crohn's disease, the development of effective inhibitors of gastric acid secretion, the role of . **alpha.4**.beta.7 **integrin** in the development of Crohn's disease and ulcerative colitis, the parts played by the neuropeptides ghrelin and motilin in the control of gastrointestinal motility, and the role of bacteria in functional gastrointestinal disease.

L20 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1006666 CAPLUS Full-text
DOCUMENT NUMBER: 145:377339
TITLE: Preparation of imidazo[1,2-a]pyridine derivatives useful as medicaments for treating gastrointestinal diseases
INVENTOR(S): Bamford, Mark James; **Elliott, Richard Leonard**; Giblin, Gerard Martin Paul; Naylor, Antoinette; **Witherington, Jason**; Panchal, Terence Aaron; Demont, Emmanuel Hubert
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 128pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006100119	A1	20060928	WO 2006-EP2952	20060322

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:	GB 2005-6137	A	20050324
	GB 2005-7101	A	20050407
	GB 2005-12923	A	20050624
	GB 2005-21274	A	20051019

OTHER SOURCE(S): MARPAT 145:377339
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = NH, N-alkyl, O; R1 = H, cyclo/alkyl, alkoxy, NH2 and derivs., etc.; R2 = cyclo/halo/alkyl, NH2, etc.; R3 = H, alkyl; R4, R5 = independently H, alkyl, OH, halo, alkoxy, NH2 and derivs.; or R3CCCR4 = (un)substituted 5- to 6-membered carbocyclyl or heterocyclyl; R6 = H, alkyl, halo, OH, NHCO2-alkyl, NH2 and derivs.; Ar = (un)substituted aryl, 5- to 6-membered monocyclyl or 7- to 12-membered bicyclyl heteroaryl; and their pharmaceutically acceptable salts; with the exception of one specified compound] were prepared for treating diseases or disorders where an acid pump antagonist is required such as gastrointestinal diseases associated with an imbalance in gastric acid (no data). Thus, cyclization of 2-amino-3,5-dibromopyridine with 3-bromo-2-butanone, reaction of the dibromide with (2,6-dimethylphenyl)methanol, and Pd-coupling of the bromide with phenylboronic acid gave imidazopyridine II. Selected I were tested in H+/K+-ATPase activity assays.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 2006:1001119 CAPLUS Full-text
DOCUMENT NUMBER: 146:213
TITLE: Pyridone derivatives as potent, orally bioavailable VLA-4 integrin antagonists
AUTHOR(S): **Witherington, Jason**; Blaney, Emma L.; Bordas, Vincent; **Elliott, Richard L.**; Gaiba, Alessandra; Garton, Neil; Green, Philip M.; Naylor, Antoinette; Smith, David G.; Spalding, David J.; Takle, Andrew K.; Ward, Robert W.
CORPORATE SOURCE: Department of DMPK and Medicinal Chemistry, Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research Limited, Essex, CM19 5AW, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(21), 5538-5541
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:213
AB A series of pyridone-N-benzylpropanoic acids have been optimized to afford potent orally bioavailable VLA-4 antagonists.
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:453930 CAPLUS Full-text
DOCUMENT NUMBER: 144:480470
TITLE: Pyridone derivatives as potent and selective VLA-4 integrin antagonists. [Erratum to document cited in CA144:403837]
AUTHOR(S): **Witherington, Jason**; Bordas, Vincent; Gaiba, Alessandra; Green, Phil M.; Naylor, Antoinette; Parr, Nigel; Smith, David G.; Takle, Andrew K.; Ward, Robert W.
CORPORATE SOURCE: Department of Medicinal Chemistry, Neurology & GI

Centre of Excellence for Drug Discovery, GlaxoSmithKline Research Limited Harlow, Essex, CM19 5AW, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(12), 3341
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The legends to Figures 1b and 3b are incorrect. In Figure 1b, the legend should read: "GASP molecular overlay of 8 (green) and 5 (yellow)". In Figure 3b, the legend should read: "Molecular overlay of 8 (green) and 10 (yellow)".

L20 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 2006:232883 CAPLUS Full-text
DOCUMENT NUMBER: 144:403837
TITLE: Pyridone derivatives as potent and selective VLA-4 integrin antagonists
AUTHOR(S): **Witherington, Jason**; Bordas, Vincent; Gaiba, Alessandra; Green, Phil M.; Naylor, Antoinette; Parr, Nigel; Smith, David G.; Takle, Andrew K.; Ward, Robert W.
CORPORATE SOURCE: Department of Medicinal Chemistry, Neurology & GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research Limited, Essex, CM19 5AW, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(8), 2256-2259
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:403837
GI



I

AB A novel series of pyridone inhibitors has been identified through pharmacophore anal., as potent antagonists of VLA-4. Analog I exhibited excellent inhibitory potency.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 8 OF 16 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

ACCESSION NUMBER: 2007:187178 BIOSIS Full-text
DOCUMENT NUMBER: PREV200700193313
TITLE: Copper homeostasis: use of in vitro cell systems and transcriptional analysis to detect markers of copper regulation in human subjects.
AUTHOR(S): Wortley, G. M. [Reprint Author]; **Elliott, R. M.** ; Harvey, L. J.; Fairweath-Tait, S. J.
CORPORATE SOURCE: Hong Kong Polytech Univ, Fac Hlth and Social Sci, Kowloon, Hong Kong, Peoples R China
SOURCE: Proceedings of the Nutrition Society, (2006) Vol. 65, No. Suppl. S, pp. 103A.
Meeting Info.: Meeting on Interactions Between Genetics, Diet, Health and Disease. Aberdeen, UK. July 03 -06, 2006.
CODEN: PNUSA4. ISSN: 0029-6651.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 14 Mar 2007
Last Updated on STN: 14 Mar 2007

L20 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 6
ACCESSION NUMBER: 2005:823674 CAPLUS Full-text
DOCUMENT NUMBER: 143:229873
TITLE: Preparation of 2-(phenylmethyl)pyrimidinones and related compounds as **alpha-4 integrin** mediated **cell adhesion** inhibitors for the treatment of inflammatory diseases
INVENTOR(S): Ward, Robert William; **Witherington, Jason**
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005075438	A1	20050818	WO 2005-JP2194	20050208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2554705	A1	20050818	CA 2005-2554705	20050208
EP 1737826	A1	20070103	EP 2005-710195	20050208
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1918133	A	20070221	CN 2005-80004473	20050208
PRIORITY APPLN. INFO.:			GB 2004-2812 A	20040209

OTHER SOURCE(S): MARPAT 143:229873
GI



I



II

AB Title compds. I [R1' = (R1)m; R2' = (R2)n; D = (CH2)t; R3' = (R3)p; R1, R2, R3 = alkyl, halo, alkoxy, etc.; R4, R4' = H, alkyl, halo, etc.; V = O, S, NH, etc.; W, X, Y, Z = C, CH, N, subject to the proviso that at least one X Y and Z is N; L = (CH2)q, (CH2)q'O; J = bond, CR5=CR6, CHR7CHR8, etc.; R5, R6 = H, alkyl; R7, R8 = H, alkyl, cycloalkyl, etc.; q = 0-3; q' = 2,3; A, B, D = aryl, heteroaryl; m, n, p = 0-3; t = 0-2] and their pharmaceutically acceptable salts were prepared For example, saponification of Et ester II (G = OEt) afforded carboxylic acid II (G = OH). Compoounds I are claimed to be useful as **alpha-4 integrin** mediated **cell adhesion** inhibitors (no data provided).

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 7
ACCESSION NUMBER: 2005:1025806 CAPLUS Full-text
DOCUMENT NUMBER: 143:299147
TITLE: Medicine compositions containing pyridone analogs for inhibiting .**alpha**.**4**-**integrin**-mediated **cell adhesion**
INVENTOR(S): **Witherington, Jason; Elliott, Richard Leonard**
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 36 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005255675	A	20050922	JP 2005-33237	20050209

PRIORITY APPLN. INFO.: JP 2004-31901 A 20040209

OTHER SOURCE(S): MARPAT 143:299147

AB Medicine compns. containing pyridone analogs and their pharmacol. acceptable salts are claimed for inhibiting .alpha.4 -integrin-mediated cell adhesion for treatment of related diseases, including chronic inflammatory diseases, asthma, allergy, inflammatory bowel disease, rheumatoid arthritis, atopic dermatitis, multiple sclerosis, organ transplant rejection, cardiovascular disease, diabetes, tumor, central nervous system diseases, etc.

L20 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1341075 CAPLUS Full-text

DOCUMENT NUMBER: 144:271286

TITLE: Expression and functional analysis of genes deregulated in mouse placental overgrowth models: Car2 and Ncam1

AUTHOR(S): Singh, Umashankar; Sun, Tong; Shi, Wei; Schulz, Ralph; Nuber, Ulrike A.; Varanou, Aikaterini; Hemberger, Myriam C.; Elliott, Rosemary W.; Ohta, Hiroshi; Wakayama, Teruhiko; Fundele, Reinald

CORPORATE SOURCE: Department of Development and Genetics, Evolutionary Biology Center, Uppsala University, Uppsala, Swed.

SOURCE: Developmental Dynamics (2005), 234(4), 1034-1045
CODEN: DEDYEI; ISSN: 1058-8388

PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Different causes, such as maternal diabetes, cloning by nuclear transfer, interspecific hybridization, and deletion of some genes such as Esx1, Ipl, or Cdkn1c, may underlie placental overgrowth. In a previous study, we carried out comparative gene expression anal. in three models of placental hyperplasias, cloning, interspecies hybridization (IHPD), and Esx1 deletion. This study identified a large number of genes that exhibited differential expression between normal and enlarged placentas; however, it remained unclear how altered expression of any specific gene was related to any specific placental phenotype. In the present study, we focused on two genes, Car2 and Ncam1, which both exhibited increased expression in interspecies and cloned hyperplastic placentas. Apart from a detailed expression anal. of both genes during normal murine placentation, we also assessed morphol. of placentas that were null for Car2 or Ncam1. Finally, we attempted to rescue placental hyperplasia in a congenic model of IHPD by decreasing transcript levels of Car2 or Ncam1. In situ anal. showed that both genes are expressed mainly in the spongiotrophoblast, however, expression patterns exhibited significant variability during development. Contrary to expectations, homozygous deletion of either Car2 or Ncam1 did not result in placental phenotypes. However, expression anal. of Car3 and Ncam2, which can take over the function of Car2 and Ncam1, resp., indicated a possible rescue mechanism, as Car3 and Ncam2 were expressed in spongiotrophoblast of Car2 and Ncam1 mutant placentas. On the other hand, downregulation of either Car2 or Ncam1 did not rescue any of the placental phenotypes of AT24 placentas, a congenic model for interspecies hybrid placentas. This strongly suggested that altered expression of Car2 and Ncam1 is a downstream event in placental hyperplasia.

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 8

ACCESSION NUMBER: 2004:143107 CAPLUS Full-text
DOCUMENT NUMBER: 140:199207
TITLE: Preparation of pyridones as inhibitors of . **alpha.4 integrin** -mediated **cell adhesion.**
INVENTOR(S): **Witherington, Jason; Elliott, Richard Leonard**
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014859	A2	20040219	WO 2003-JP10119	20030808
WO 2004014859	A3	20040415		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493660	A1	20040219	CA 2003-2493660	20030808
AU 2003256069	A1	20040225	AU 2003-256069	20030808
EP 1539696	A2	20050615	EP 2003-784602	20030808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1688548	A	20051026	CN 2003-823831	20030808
JP 2005535702	T	20051124	JP 2004-527373	20030808
US 2005288337	A1	20051229	US 2005-524028	20050209

PRIORITY APPLN. INFO.: GB 2002-18630 A 20020810
WO 2003-JP10119 W 20030808

OTHER SOURCE(S): MARPAT 140:199207
GI



I

AB Title compds. [I; A, B = aryl, heteroaryl; Q = C, CH; QV, QD = 5-7 membered heterocyclyl; D = H, alkyl; R1-R3 = alkyl, halo, alkoxy, OH, cyano, CF3, NO2, alkylthio, amino, CO2H, alkanoyl, amido, NHCOR9, NHSO2R9; R9 = alkyl, cycloalkyl, (substituted) Ph etc.; R4 = H, alkyl, halo, alkoxy; V = O, S,

amino, NNO2, NCN; W, X, Y, Z = C, CH, CH2; dotted line = single or double bond; L = (CH2)r, (CH2)rrO; r = 0-3; rr = 2, 3; J = CR5:CR6, CHR7CHR8, single bond, CHR6; OCHR10, etc.; R5, R6, R10 = H, alkyl; R7, R8 = H, alkyl, cycloalkyl, aryl, heteroaryl, etc.; m, n, p = 0-3; q = 0-2], were prepared as inhibitors of . **alpha.4 integrin**-mediated **cell adhesion** (no data). Thus, Et 3-[4-[2-oxo-3-[4-(3-o- tolylureido)phenyl]-2H-pyridin-1-ylmethyl]phenyl]propionate and LiOH were stirred at 60° for 30 min in THF/H2O to give after acidification with HCl 3-[3-[2-oxo-3-[4-(3-o-tolylureido)phenyl]-2H- pyridin-1-ylmethyl]phenyl]propionic acid.

L20 ANSWER 13 OF 16 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

ACCESSION NUMBER: 2004:198917 BIOSIS Full-text
DOCUMENT NUMBER: PREV200400199476
TITLE: Microarray analysis reveals functional clustering of gene expression in dentate granule cells over extended timecourses of development and epileptogenesis.
AUTHOR(S): **Elliott, R. C.** [Reprint Author]; Otu, H.; Kruegel, B. R. [Reprint Author]; Usta, F.; Libermann, T.; Lowenstein, D. H.
CORPORATE SOURCE: Neurol., Beth Israel Deaconess Med. Ctr., Boston, MA, USA
SOURCE: Society for Neuroscience Abstract Viewer and Itinerary Planner, (2003) Vol. 2003, pp. Abstract No. 411.1. http://sfn.scholarone.com. e-file.
Meeting Info.: 33rd Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 08-12, 2003. Society of Neuroscience.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 14 Apr 2004
Last Updated on STN: 14 Apr 2004

AB Prior findings in our laboratory support the concept that molecular mechanisms underlying aspects of dentate granule cell (DGC) development may play important roles in epilepsy-associated DGC plasticity. To define and compare patterns of DGC gene expression during development and epileptogenesis further, we have performed microarray analyses over the first 28 postnatal days of rat DGC development and the first 60 days following pilocarpine-induced status epilepticus (SE) in a rodent model of human temporal lobe epilepsy. Of the 8800 genes on the Affymetrix microarrays used, approximately 700 genes were found to be regulated at one or more of 5 developmental timepoints analyzed. Half this number, or roughly 350 genes, were found to be regulated during one or more of 5 timepoints following SE. Self-organizing map (SOM) analysis of these regulated genes indicates that those with similar gene product function often share similar temporal profiles of expression. For instance, six different genes involved in calcium homeostasis/signaling that were down-regulated during epileptogenesis were grouped in two similarly-shaped clusters, and nine different sequences representing Major Histocompatibility Complex (MHC) family members were up-regulated with one of two distinct patterns following SE. In addition, nearly 100 genes were regulated during both development and epileptogenesis. Two genes, coding for the **cell adhesion** molecules neurotrimin and LAMP, co-clustered in developmental and epileptogenesis profiles that were very similar to each other. These results provide additional evidence of a reiteration of developmental mechanisms during epileptogenesis.

L20 ANSWER 14 OF 16 MEDLINE on STN DUPLICATE 9

ACCESSION NUMBER: 85225713 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 4004930
TITLE: Relationship of biochemical drug effects to their antitumor activity--II. Diacridines and membrane-related reactions.
AUTHOR: **Elliott R E**; Karadsheh N S; Kole J; Canellakis E S
CONTRACT NUMBER: CA 28852 (NCI)
GM 03070 (NIGMS)
SOURCE: Biochemical pharmacology, (1985 Jun 15) Vol. 34, No. 12, pp. 2123-8.
Journal code: 0101032. ISSN: 0006-2952.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198507
ENTRY DATE: Entered STN: 20 Mar 1990
Last Updated on STN: 3 Feb 1997
Entered Medline: 10 Jul 1985

AB A method is presented that determines the degree of attachment of cancer cells to normal cells. This method may be useful in determining the extent to which treatment of normal cells (or of a tumor-bearing host) with a particular chemotherapeutic agent may affect the degree of attachment of cancer cells to the normal cells. The effects of several diacridines upon this process are described. In addition, we have determined the ability of individual diacridines to alter the permeability of P-388 cells; this effect has been related to their antitumor properties. In general, the most effective antitumor diacridines are those that cause minimal disruption of cell permeability. Conversely, diacridines that disrupt cell permeability tend to have poor antitumor properties. It is considered that the toxicity of these compounds may be a necessary consequence of the assays used for testing anticancer agents, and may not necessarily be related to their antitumor activity.

L20 ANSWER 15 OF 16 JAPIO (C) 2007 JPO on STN
ACCESSION NUMBER: 2007-063268 JAPIO Full-text
PATENT INFORMATION:

PATENT NO	KIND	DATE	ERA	MAIN IPC
JP 2007063268	A	20070315	Heisei	

APPLICATION INFORMATION
STN FORMAT: JP 2006-212923 20060804
ORIGINAL: JP2006212923 Heisei
PRIORITY APPLN. INFO.: JP 2005-227980 20050805
SOURCE: PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 2007
AN 2007-063268 JAPIO Full-text

L20 ANSWER 16 OF 16 JAPIO (C) 2007 JPO on STN
ACCESSION NUMBER: 2005-255675 JAPIO Full-text
TITLE: PHARMACEUTICAL COMPOSITION
INVENTOR: **WITHERINGTON JASON**; ELLIOT RICHARD LEONARD
PATENT ASSIGNEE(S): TANABE SEIYAKU CO LTD
PATENT INFORMATION:

PATENT NO	KIND	DATE	ERA	MAIN IPC
JP 2005255675	A	20050922	Heisei	A61K031-4418

APPLICATION INFORMATION
STN FORMAT: JP 2005-33237 20050209
ORIGINAL: JP2005033237 Heisei
PRIORITY APPLN. INFO.: JP 2004-31901 20040209
SOURCE: PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 2005

AN 2005-255675 JAPIO Full-text

AB PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition effectively suppressing or inhibiting α<SB>4</SB>-integrin- interposed **cell adhesion** and effective for preventing or treating chronic inflammatory diseases. SOLUTION: This pharmaceutical composition contains as active ingredient a compound of formula(I) having α<SB>4</SB>-integrin- interposed **cell adhesion** inhibitory activity or a pharmaceutically acceptable derivative thereof. COPYRIGHT: (C)2005,JPO&NCIPI

FILE 'HOME' ENTERED AT 15:19:56 ON 20 JUL 2007

L1 STR



VAR G1=O/S/N
REP G2=(0-3) CH2
REP G3=(0-3) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 11
GGCAT IS MCY AT 15
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E5 C E1 N AT 13

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L2 STR



VAR G1=O/S/N
REP G2=(0-3) CH2
REP G3=(2-3) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 11
GGCAT IS MCY AT 18
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E5 C E1 N AT 13

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L3 STR



VAR G1=O/S/N
REP G2=(0-3) CH2
REP G3=(0-3) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1 N AT 13

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L4 STR



VAR G1=O/S/N
REP G2=(0-3) CH2
REP G3=(2-3) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1 N AT 13

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L5 (132)SEA FILE=REGISTRY SSS FUL L3 OR L4
L6 77 SEA FILE=REGISTRY SUB=L5 SSS FUL (L1 OR L2)

(FILE 'REGISTRY' ENTERED AT 12:05:43 ON 24 JUL 2007)
ACT DAVIS524028/A

L1 STR
L2 STR
L3 STR
L4 STR
L5 (132)SEA SSS FUL L3 OR L4
L6 77 SEA SUB=L5 SSS FUL (L1 OR L2)

FILE 'REGISTRY' ENTERED AT 12:07:25 ON 24 JUL 2007
D QUE STAT

FILE 'CAPLUS' ENTERED AT 12:07:25 ON 24 JUL 2007
L7 5 SEA ABB=ON PLU=ON L6
D 1-5

FILE 'REGISTRY' ENTERED AT 12:09:19 ON 24 JUL 2007
L8 72 SEA ABB=ON PLU=ON (660439-93-0/BI OR 660439-96-3/BI OR
660439-99-6/BI OR 660440-22-2/BI OR 660440-23-3/BI OR
660440-62-0/BI OR 660439-94-1/BI OR 660439-95-2/BI OR
660439-97-4/BI OR 660439-98-5/BI OR 660440-00-6/BI OR
660440-01-7/BI OR 660440-02-8/BI OR 660440-03-9/BI OR
660440-05-1/BI OR 660440-07-3/BI OR 660440-12-0/BI OR
660440-13-1/BI OR 660440-14-2/BI OR 660440-15-3/BI OR
660440-16-4/BI OR 660440-17-5/BI OR 660440-18-6/BI OR
660440-19-7/BI OR 660440-20-0/BI OR 660440-21-1/BI OR
660440-24-4/BI OR 660440-25-5/BI OR 660440-26-6/BI OR
660440-27-7/BI OR 660440-28-8/BI OR 660440-29-9/BI OR
660440-30-2/BI OR 660440-31-3/BI OR 660440-32-4/BI OR
660440-33-5/BI OR 660440-34-6/BI OR 660440-35-7/BI OR
660440-36-8/BI OR 660440-37-9/BI OR 660440-38-0/BI OR
660440-39-1/BI OR 660440-40-4/BI OR 660440-41-5/BI OR
884347-98-2/BI OR 884347-99-3/BI OR 884348-00-9/BI OR
915157-68-5/BI OR 915157-69-6/BI OR 915157-70-9/BI OR
915157-71-0/BI OR 915157-72-1/BI OR 915157-73-2/BI OR
915157-74-3/BI OR 915157-75-4/BI OR 915157-76-5/BI OR
915157-77-6/BI OR 915157-78-7/BI OR 915157-79-8/BI OR
915157-80-1/BI OR 915157-81-2/BI OR 915157-82-3/BI OR
915157-83-4/BI OR 915157-84-5/BI OR 915157-85-6/BI OR
915157-86-7/BI OR 915157-87-8/BI OR 915157-88-9/BI OR
915157-89-0/BI OR 915157-90-3/BI OR 915157-91-4/BI OR
915157-93-6/BI)
D QUE
D 1-72 REG
D 1,5,9,18,26,27,29,35,42,58,66,72 IDE CAN

FILE 'CAOLD' ENTERED AT 12:11:20 ON 24 JUL 2007
L9 0 SEA ABB=ON PLU=ON L6

FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 12:11:29 ON 24 JUL 2007
L10 0 SEA ABB=ON PLU=ON L6

FILE 'HOME' ENTERED AT 12:11:39 ON 24 JUL 2007
D QUE L6

```
     FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE, WPIX, JAPIO, PASCAL, DISSABS'
     ENTERED AT 15:13:07 ON 20 JUL 2007
L15          205 SEA ABB=ON  PLU=ON  "WITHERINGTON J"?/AU
L16         6337 SEA ABB=ON  PLU=ON  "ELLIOTT R"?/AU
L17           12 SEA ABB=ON  PLU=ON  L15 AND L16
L18           24 SEA ABB=ON  PLU=ON  (L15 OR L16) AND ((ALPHA4 OR A4 OR (A
                 OR ALPHA)(W) 4)(3A) INTEGRIN OR (CD49? OR CD 49)(5A)
                 ANTIGEN OR (CELL OR CELLULAR)(3A) ADHESION)
L19           30 SEA ABB=ON  PLU=ON  L17 OR L18
L20           16 DUP REM L19 (14 DUPLICATES REMOVED)
                 D 1-16 IBIB ABS


     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   19 JUL 2007  HIGHEST RN 942942-65-6
     DICTIONARY FILE UPDATES:  19 JUL 2007  HIGHEST RN 942942-65-6

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/support/stngen/stndoc/properties.html

     FILE CAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storin
     of this information, without the prior written consent of CAS, is
     strictly prohibited.

     FILE COVERS 1907 - 20 Jul 2007  VOL 147 ISS 5
     FILE LAST UPDATED: 19 Jul 2007  (20070719/ED)

     Effective October 17, 2005, revised CAS Information Use Policies apply
     They are available for your review at:

     http://www.cas.org/infopolicy.html

     FILE CAOLD
     FILE COVERS 1907-1966
     FILE LAST UPDATED:  01 May 1997 (19970501/UP)

       This file contains CAS Registry Numbers for easy and accurate
       substance identification.  Title keywords, authors, patent
```

assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

FILE MEDLINE
FILE LAST UPDATED: 19 Jul 2007 (20070719/UP). FILE COVERS 1950 TO DA

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS
FILE COVERS 1926 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1926 TO DATE.

RECORDS LAST ADDED: 18 July 2007 (20070718/ED)

BIOSIS has been augmented with 1.8 million archival records from 1926 through 1968. These records have been re-indexed to match current BIOSIS indexing.

FILE EMBASE
FILE COVERS 1974 TO 20 Jul 2007 (20070720/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE WPIX
FILE LAST UPDATED: 16 JUL 2007 <20070716/UP>
MOST RECENT THOMSON SCIENTIFIC UPDATE: 200745 <200745/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> IPC Reform backfile reclassification has been loaded to 31 May 2007. No update date (UP) has been created for the reclassified documents, but they can be identified by 20060101/UPIC and 20061231/UPIC and 20060601/UPIC. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomson.com/support/patents/coverage/latestupdates/

>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX PLEASE SEE
http://www.stn-international.de/stndatabases/details/dwpi_r.html <<<

FILE JAPIO
FILE LAST UPDATED: 4 JUL 2007 <20070704/UP>

FILE COVERS APRIL 1973 TO MARCH 29, 2007

>>> GRAPHIC IMAGES AVAILABLE <<<

FILE PASCAL
FILE LAST UPDATED: 18 JUL 2007 <20070718/UP>
FILE COVERS 1977 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE
IN THE BASIC INDEX (/BI) FIELD <<<

FILE DISSABS
FILE COVERS 1861 TO 2 JUL 2007 (20070702/ED)

FILE HOME